(Q36058902)

11 August 2017

1 reference

title

US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles (English)

1 reference

11 August 2017

0 references

1

Steven L Galetta

1 reference

11 August 2017

Clyde Markowitz

2

1 reference

11 August 2017

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

19

1 reference

11 August 2017

3

1 reference

11 August 2017

239-252

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200519030-00005

11 August 2017

0 references

cites work

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

12 December 2020

Lipoatrophy in patients with multiple sclerosis on glatiramer acetate

1 reference

12 December 2020

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Multiple sclerosis: side effects of interferon beta therapy and their management

1 reference

12 December 2020

1 reference

12 December 2020

Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer

1 reference

12 December 2020

Fulminant liver failure during interferon beta treatment of multiple sclerosis

1 reference

12 December 2020

Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis

1 reference

12 December 2020

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

12 December 2020

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

1 reference

12 December 2020

Mitoxantrone immunotherapy in multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

12 December 2020

A replicated prospective investigation of life stress, coping, and depressive symptoms in multiple sclerosis

1 reference

12 December 2020

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS

1 reference

12 December 2020

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance

1 reference

12 December 2020

Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS.

1 reference

12 December 2020

Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Severe heart failure in a young multiple sclerosis patient

1 reference

12 December 2020

Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis

1 reference

12 December 2020

Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis.

1 reference

12 December 2020

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference

1 reference

12 December 2020

A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients

1 reference

12 December 2020

Interferon treatment for multiple sclerosis: autoimmune complications may be lethal

1 reference

12 December 2020

Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review

1 reference

12 December 2020

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

12 December 2020

Localized lipoatrophy after prolonged treatment with copolymer 1

1 reference

12 December 2020

Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

12 December 2020

Managing the adverse effects of interferon-beta therapy in multiple sclerosis

1 reference

12 December 2020

Considerations in the treatment of relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

1 reference

12 December 2020

Autoimmune hepatitis and interferon beta-1a for multiple sclerosis

1 reference

12 December 2020

Disease-modifying therapy in multiple sclerosis: strategies for optimizing management

1 reference

12 December 2020

Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel.

1 reference

12 December 2020

A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.

1 reference

12 December 2020

Long-term interferon-beta treatment for multiple sclerosis

1 reference

12 December 2020

Liver injury associated with the beta-interferons for MS: a comparison between the three products.

1 reference

12 December 2020

10.2165/00023210-200519030-00005

Identifiers

DOI

1 reference

PubMed ID

15740178

Dimensions Publication ID

11 August 2017

0 references

1 reference

PubMed ID

15740178